Perpetua Medical AB (publ) provides products and solutions for use of injectable drugs in Sweden. It provides DrugLog, a solution for reducing medication errors in pharmacy; WasteLog, a device that analysis waste and returns of injectable controlled substances; and PrepLog, a DrugLog based technology platform that integrated prescription software or medication management system for the test of drug preparations. The company formerly known as Pharmacolog i Uppsala AB (publ) and changed its name to Perpetua Medical AB (publ) in April 2024. Perpetua Medical AB (publ) was incorporated in 2007 and is headquartered in Uppsala, Sweden. Perpetua Medical AB (publ) operates as a subsidiary of Nolsterby Invest AB.…
Perpetua Medicals dotterbolag ES-Medical når uppgörelse med bolagets huvudleverantör och utvecklar nästa generations rengöringssystem för TEE-prober
Perpetua Medical (STO: PERP-B) is listed on Nasdaq Stockholm, where its shares trade in SEK. It belongs to the Medical Devices industry, part of the Healthcare sector, and reports about 12 employees.
The shares were at 1.750 SEK on 20 November 2026, down 68.1% over 52 weeks. Its 52-week range is 1.275 SEK to 5.820 SEK: the price is 69.9% below the high and 37.3% above the low.
At a market capitalisation of 14.97M SEK, it trades at 5.5 times trailing earnings. The median trailing P/E of its 19 largest Medical Devices peers is 25.5, a discount of 79% for PERP-B.
Perpetua Medical reports return on equity of 12.4%, an operating margin of -12.1% and revenue up 120.8% year over year.
It holds more cash than debt, a net cash position of 4.27M SEK. Its Piotroski F-score is 4 out of 9, an average reading of its financial health.
No upcoming events tracked.